Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0012833 (
dizziness
)
9,689
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Researchers analyzed data on 1572 18-44 year old women attending 1 of 10 institutions in 7 provinces and cities in China to examine the side effects of oral administration of 600 mg
RU-486
followed by 1 mg of a prostaglandin (PG05) vaginal suppository and this combination's efficacy in terminating early pregnancy. Incomplete abortion occurred in 4.8% of the women; continuation of pregnancy, in 3.9%. 91.2% of the women experienced a complete abortion, which took an average of 2.4 days. Just 3.3% of the women experienced expulsion before insertion of the PG05 vaginal suppository. 81% expelled the fetal sac within 6 hours after PG05 insertion. 88% of women with complete abortion had bleeding on day 2 or 3 and bled on average 11.7 days. 24.5% experienced bleeding for more than 14 days; the bleeding was heavy for 47.4% of them. 1 women bled so profusely she required 2 blood transfusions. The leading side effects were nausea and vomiting (22.3%), abdominal pain (10.2%), headache and
dizziness
(4.1%), diarrhea (2.8%), and thirst (1.2%). 79.5-96.2% of subjects considered these side effects to be mild or moderate. The side effects persisted for 17-36 hours. None of the women experienced any serious complications that sometimes occur with intramuscularly injected prostaglandins. 92% of the women who experienced complete abortion considered this method to be at least good. The corresponding figure for the incomplete abortion and failed groups was 26.3% and 41.9%, respectively. The researchers concluded that this combination was effective and safe for termination of early pregnancy. They suggested that health workers counsel the women before treatment to increase tolerance of the mild to moderate side effects.
...
PMID:Clinical trial on termination of early pregnancy with RU486 in combination with prostaglandin. 145 16
The safety and effectiveness of oral methotrexate and vaginal misoprostol for early abortion were evaluated in a prospective study of 300 women who presented to the Cuidad de la Habana (Havana, Cuba) for termination of a pregnancy of a gestational age of 63 days or less. All women were given 50 mg of methotrexate at study entry and then were randomly allocated to receive 800 mcg of misoprostol either 3, 4, or 5 days later. If abortion did not occur, misoprostol was readministered 48 and 96 hours later. Complete abortion occurred in 273 women (91%); the success rate was 72% (216 cases) after just one dose of misoprostol. There were no significant differences in abortion rates based on the day on which misoprostol was administered. Vaginal bleeding lasted an average of 7.1 +or- 3.8 days, spotting continued for 4.1 +or- 2.5 days, and total bleeding persisted for 11.2 +or- 4.1 days. Side effects for methotrexate included nausea (9.7%), vomiting (6.7%),
dizziness
(10.3%), fatigue (6.3%), headache (5.3%), and chills (5.3%). For misoprostol, side effects included nausea (23.0%), vomiting (25.3%), diarrhea (51.7%),
dizziness
(18.3%), headache (18.0%), chills (60.0%), and pelvic pain (97.3%). All signs and symptoms were of low intensity and short duration, however. These results suggest that combined use of methotrexate and misoprostol represents a feasible alternative to the intramuscular use of methotrexate or of antiprogestins and prostaglandin for medical abortion. The efficacy and safety of this new regimen are very close to those of
RU-486
, but the cost is considerably less.
...
PMID:Oral methotrexate and vaginal misoprostol for early abortion. 958 33
Women who do not have contraindications for oral contraceptives (OCs) and have experienced failure of their contraceptive method or used no contraceptive at all an use emergency postcoital contraceptive pills (ECPs). In fact, if used correctly, they could prevent 1.7 million unplanned pregnancies each year which is 50% lower than such pregnancies which already occur each year. They could also reduce the number of annual induced abortions by 50% from (1.6 million to 800,000). Various postcoital treatments in the US are 2 pills of Ovral within 72 hours of intercourse then 2 more pills 12 hours later and 4 pills of either Lo/Ovral, Nordette, Levlen, Triphasil, or Tri-Levlen followed by 4 more pills 12 hours later. Some gynecologists contend that any low-dose combined OC could be used as an ECP, but not study proves this. Besides, providers who do so risk a malpractice suit, because postcoital contraception is not on OC labels. An attorney suggests using OCs only for an emergency and to document all attempts at informed consent. Many children and clinicians have limited or no knowledge about ECPs. Those health providers who are familiar with them tend not to prescribe them because they fear legal actions. ECP side effects include severe nausea or vomiting, headache, breast tenderness,,
dizziness
, and fluid retention. These effects are not as great as the health risks of unplanned pregnancies, however. Yet, they are unpleasant enough to discourage repeated ECP use. Use of different methods of determining the number of pregnancies has resulted in broad ECP effectiveness rates (0-96% and 56-94%). Another analysis using combined data from the studies yielding the various results shows the effectiveness rate to be 75%. Anti-abortion groups may object to ECP use, just as they do for
RU-486
which has fewer side effects, because one of its mechanisms of preventing pregnancy is it prevents implantation.
...
PMID:Postcoital pills could cut unplanned pregnancies by half. 1231 83